Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
-
Gueorguieva, Ivelina (Eli Lilly and Company (United Kingdom))
;
Cleverly, Ann (Eli Lilly and Company (United Kingdom)) ;
Desaiah, Durisala (Eli Lilly and Company (USA)) ;
Azaro, Analía (Hospital Universitari Vall d'Hebron) ;
Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ;
Braña, Irene (Hospital Universitari Vall d'Hebron) ;
Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ;
Miles, Colin (Eli Lilly and Company (United Kingdom)) ;
Lahn, Michael M.. (Eli Lilly and Company (USA)) ;
Mitchell, Malcolm I (Eli Lilly and Company (USA)) ;
Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
visitant ::
identificació
Subscriure's to this discussion. You will then receive all new comments by email.
